Pelthos Therapeutics

PTHS

Market cap $77.2M

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease

Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript

Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $3.95. This compares to a loss of $3.2 per share a year ago.

ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025.

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that CEO Scott Plesha will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026 at 3:00 p.m. Pacific Time.

FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) (“Pelthos”), with an initial funding of $30 million, and up to $20 million to support future growth. Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI™ (berdazimer) topical gel, an.

The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes

DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million.

Pelthos Pharmaceuticals has launched Zelsuvmi, the first at-home FDA-approved treatment for molluscum contagiosum, showing strong initial sales growth. PTHS reported $7.1 million net revenue in its first commercialization quarter, prompting an expansion of its sales force. The company targets breakeven by end-2026, with peak revenue projections of $175 million likely conservative given rapid prescription uptake and market size.

Pelthos Therapeutics Inc. ( PTHS ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Mike Moyer Scott Plesha - CEO, President & Director Sai Rangarao Francis Knuettel - Chief Financial Officer Conference Call Participants Jeffrey Jones - Oppenheimer & Co. Inc., Research Division James Molloy - Alliance Global Partners, Research Division Presentation Operator Greetings, and welcome to the Pelthos Therapeutics Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note, this conference is being recorded.